CD274 and nasopharyngeal carcinoma: We previously reported a phase II study (NCT04396886) using bintrafusp alfa, a dual inhibitor of TGFβ and PD‐L1, in 38 resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) patients.